Aims: The aim of this study is to determine the sustained therapeutic efficacy and treatment intervals for PTNS in NOAB with MS, offering periodic additional treatments during 1 year in patients who completed an initial course of 12 consecutive weekly sessions. Methods: A total of 34 patients enrolled to the PTNS treatment and 21 patients completed the 1 year PTNS treatment with a tapering protocol of 6, 9, and 12 months of therapy, respectively. After 12 weeks of therapy, PTNS was applied at 14 day intervals for 3 months, 21 day intervals for 3 months, and 28 day intervals for 3 months. The patients completed a 3-day voiding diary at 3rd, 6th, 9th, and 12th month. The patients requested to complete validated questionnaires (ICIQ-SF, OAB-V8...
PURPOSE: This study was designed to investigate the safety and performance of a new implantable syst...
Aims Sexual dysfunction (SD) is common in female patients with multiple sclerosis (MS) reporting ove...
Background: While intravesical injections of botulinum neurotoxin A (BoNT-A) are currently recommend...
Aims: The aim of this study is to determine the sustained therapeutic efficacy and treatment interva...
Objective: In this study, it was aimed to determine the effectiveness of percutaneous tibial nerve s...
IntroductionNeurogenic bladder is frequently seen in patients with multiple sclerosis (MS). Electric...
PURPOSE: Percutaneous tibial nerve stimulation is a minimally invasive neuromodulation technique for...
Aim: Overactive Bladder Syndrome (OAB) is characterized by a series of urinary symptoms such as inco...
Background and purposePosterior tibial nerve stimulation (PTNS) is an effective treatment option for...
OBJECTIVES: To identify factors influencing return for maintenance Percutaneous tibial nerve stimula...
PURPOSE: Recently, intermittent percutaneous posterior tibial nerve stimulation was introduced as a ...
Introduction and objectives: Overactive bladder syndrome (OAB) is defined as urinary urgency, with o...
Background: Overactive bladder (OAB) symptoms of frequency, urgency and urge incontinence are freque...
Background: Antimuscarinics (AMs) represent the mainstay of treatment for storage lower urinary trac...
OBJECTIVES: To determine urodynamic changes and predictive factors in patients with voiding dysfunct...
PURPOSE: This study was designed to investigate the safety and performance of a new implantable syst...
Aims Sexual dysfunction (SD) is common in female patients with multiple sclerosis (MS) reporting ove...
Background: While intravesical injections of botulinum neurotoxin A (BoNT-A) are currently recommend...
Aims: The aim of this study is to determine the sustained therapeutic efficacy and treatment interva...
Objective: In this study, it was aimed to determine the effectiveness of percutaneous tibial nerve s...
IntroductionNeurogenic bladder is frequently seen in patients with multiple sclerosis (MS). Electric...
PURPOSE: Percutaneous tibial nerve stimulation is a minimally invasive neuromodulation technique for...
Aim: Overactive Bladder Syndrome (OAB) is characterized by a series of urinary symptoms such as inco...
Background and purposePosterior tibial nerve stimulation (PTNS) is an effective treatment option for...
OBJECTIVES: To identify factors influencing return for maintenance Percutaneous tibial nerve stimula...
PURPOSE: Recently, intermittent percutaneous posterior tibial nerve stimulation was introduced as a ...
Introduction and objectives: Overactive bladder syndrome (OAB) is defined as urinary urgency, with o...
Background: Overactive bladder (OAB) symptoms of frequency, urgency and urge incontinence are freque...
Background: Antimuscarinics (AMs) represent the mainstay of treatment for storage lower urinary trac...
OBJECTIVES: To determine urodynamic changes and predictive factors in patients with voiding dysfunct...
PURPOSE: This study was designed to investigate the safety and performance of a new implantable syst...
Aims Sexual dysfunction (SD) is common in female patients with multiple sclerosis (MS) reporting ove...
Background: While intravesical injections of botulinum neurotoxin A (BoNT-A) are currently recommend...